Immatics (IMTX)
(Delayed Data from NSDQ)
$11.00 USD
+0.17 (1.57%)
Updated May 13, 2024 04:00 PM ET
After-Market: $10.99 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
IMTX 11.00 +0.17(1.57%)
Will IMTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IMTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMTX
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
IMTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
Other News for IMTX
IMTX Crosses Above Key Moving Average Level
Immatics N.V.: An Intriguing Developmental Concern
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)